|
|
| | VU6005806 Basic information |
| Product Name: | VU6005806 | | Synonyms: | VU6005806;AZN-00016130;VU6005806,VU-6005806;Thieno[2,3-c]pyridazine-6-carboxamide, 5-amino-3-methoxy-4-methyl-N-[1-[5-(trifluoromethyl)-2-pyrimidinyl]-3-azetidinyl]- | | CAS: | 2180914-37-6 | | MF: | C17H16F3N7O2S | | MW: | 439.41 | | EINECS: | | | Product Categories: | | | Mol File: | 2180914-37-6.mol |  |
| | VU6005806 Chemical Properties |
| density | 1.59±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 11.44±0.20(Predicted) |
| | VU6005806 Usage And Synthesis |
| Description | VU6005806 (AZN-00016130) is a potent muscarnic acethylcholine receptor subtype 4 (M4) positive allosteric modulator (PAM), with EC50s of 94 nM, 28 nM, 87 nM and 68 nM for human, rat, dog and cyno M4, respectively. Used in the research of neuropsychiatric disorders[1].
IC50: 94 nM (Human M4), 28 nM (Rat M4), 87 nM (Dog M4), 68 nM (Cyno M4)[1] | | Uses | VU6005806 (AZN-00016130) is a potent muscarnic acethylcholine receptor subtype 4 (M4) positive allosteric modulator (PAM), with EC50s of 94 nM, 28 nM, 87 nM and 68 nM for human, rat, dog and cyno M4, respectively. Used in the research of neuropsychiatric disorders[1]. | | References | [1]. Engers DW, et al. VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. Bioorg Med Chem Lett. 2019 Jul 15;29(14):1714-1718. |
| | VU6005806 Preparation Products And Raw materials |
|